FDA’s 2026 Peptide Compounding Policy Explained
On Oct 28 2026 the U.S. Food and Drug Administration released an interim enforcement discretion policy that lets state-licensed 503A pharmacies compound six specific peptides for individual patients. Here is exactly what the policy does-and does not-change.
The FDA’s Oct 28 2026 interim enforcement discretion policy allows 503A compounding pharmacies to prepare prescription versions of six research peptides-BPC-157, TB-500, KPV, MOTS-c, Semax and Epitalon-when a licensed prescriber orders them for an individual patient. The policy is temporary, does not add these peptides to the official 503A bulks list and is not an FDA approval. Compounders must meet specific requirements for ingredient quality, manufacturing standards, labeling and safety reporting, and state boards of pharmacy may still restrict or ban the practice. Patients should work only with licensed U.S. providers and pharmacies and avoid “research use only” sellers that remain outside the policy.
- The interim policy covers exactly six peptides: BPC-157, TB-500, KPV, MOTS-c, Semax and Epitalon.
- It is an enforcement discretion policy, not an FDA approval or an expansion of the 503A bulks list.
- Compounders must meet the policy's conditions on ingredient quality, manufacturing standards, labeling and safety reporting.
- FDA's Pharmacy Compounding Advisory Committee (PCAC) recommended the six peptides in July 2026, even though FDA staff reviewers had recommended against them.
- State boards of pharmacy can still prohibit or restrict compounding the peptides, so access will vary by state (Quesada et al., 2026).
- Rx.com plans to offer prescription compounded versions of these peptides through U.S.-licensed providers and a licensed 503A pharmacy (coming soon).
What the 2026 FDA peptide policy is
The policy is an interim “enforcement discretion” statement. That means FDA says it does not intend to take enforcement action against qualifying 503A pharmacies or physicians who compound the six peptides for individual patients, as long as they follow the policy’s conditions. It is published jointly by the Department of Health and Human Services (HHS) and FDA and has no sunset date, though HHS states it may revise or withdraw the policy if safety or quality problems emerge.
Enforcement discretion does not change the law. It means FDA has decided not to act against compounders that meet the policy's conditions, while the underlying rules stay in place.
Which six peptides are covered
Only six peptides qualify. If a peptide is not on this short list, nothing in the policy changes its status.
| Peptide | FDA-approved status | Covered by policy? |
|---|---|---|
| BPC-157 | No | Yes |
| TB-500 | No | Yes |
| KPV | No | Yes |
| MOTS-c | No | Yes |
| Semax | No | Yes |
| Epitalon | No | Yes |
Why these six? In July 2026 FDA's Pharmacy Compounding Advisory Committee voted to recommend them, even though FDA staff reviewers had recommended against. The reviewers found no human safety studies for KPV, TB-500, MOTS-c or Epitalon, and found the BPC-157 human studies too small and too short.
⚠️ Emideltide was left out
Emideltide was not included in the policy, so nothing in it changes emideltide's status. The same is true of every other peptide outside the six, including GHK-Cu, ipamorelin and CJC-1295.
Why enforcement discretion is not approval
None of the six peptides is FDA-approved. The policy does not evaluate efficacy, safety or quality like a New Drug Application would. It simply says FDA will “exercise discretion” and decline to take action as long as compounders meet the listed conditions.
Human evidence remains limited. BPC-157, for example, has no completed Phase II trial (Mateescu et al., 2026).
The policy also does not place the peptides on the Section 503A bulks list that formally authorizes bulk drug substances for compounding. That list still requires a separate rulemaking process, explained in detail in our bulks-list guide.
Conditions compounders must meet
The policy sets conditions in four areas. A 503A pharmacy or physician compounding one of the six peptides must meet the policy's conditions on:
1. Ingredient quality: the quality of the peptide ingredient used.
2. Manufacturing standards: how the medication is prepared.
3. Labeling: what the dispensed product's label must say.
4. Safety reporting: reporting adverse events and safety problems to FDA.
| Requirement category | Why it matters for patients |
|---|---|
| Ingredient quality | Reduces risk of contaminants or wrong peptide sequence |
| Manufacturing standards | Aligns with existing sterile compounding safeguards |
| Labeling | Makes it clear the product is unapproved and patient-specific |
| Safety reporting | Creates a paper trail for adverse events so FDA can act if problems emerge |
How state rules influence access
States are not bound by the federal policy. Each state board of pharmacy can decide whether to allow, restrict or ban compounding of the six peptides. States also differ in telehealth prescribing rules and nurse-practitioner authority, creating a patchwork of access levels across the country (Quesada et al., 2026).
Before filling any peptide prescription, verify that: (1) your prescriber is licensed in your state; (2) the pharmacy holds a current state license; (3) your state board has not issued a prohibition or emergency order against these peptides.
What the policy leaves out
No end date. The policy is interim and has no stated end date. HHS may reconsider it if safety or quality problems emerge.
Citizen petition in opposition. A citizen petition asking FDA to block the policy was filed the week before the policy was published.
What patients can do now
1. Work with a licensed provider. Avoid “research use only” websites that are explicitly outside the enforcement policy and often ship unknown-quality products.
2. Verify the pharmacy. Ask for the pharmacy’s state license number and confirm it on your state board’s website.
3. Ask questions. A licensed pharmacy should be able to explain how it meets the policy's conditions and what is on your label.
4. Report problems quickly. If you experience an adverse reaction or notice a product quality issue, submit a MedWatch report yourself in addition to telling your prescriber.
5. Stay informed. The policy is interim. Monitor FDA announcements and state board updates. This guide will be updated as changes occur.
Coming soon from Rx.com: Rx.com plans to offer prescription compounded versions of BPC-157, TB-500, KPV, MOTS-c, Semax and Epitalon through U.S.-licensed providers and a licensed 503A pharmacy (coming soon).
Should you pursue a compounded peptide prescription now?
Check the column that fits your situation:
✅ Probably OK to proceed
- You have consulted a licensed U.S. provider who understands peptide therapy
- You can confirm the pharmacy is 503A-licensed in your state
- You accept that benefits are unproven and results vary
- You are prepared to monitor and report any side effects promptly
- You prefer a prescription product over a “research use only” vial or powder
🏥 Talk to your doctor first
- You expect guaranteed healing or performance benefits
- You are pregnant, breastfeeding or planning pregnancy
- You cannot verify the pharmacy’s license or ingredient source
- You are considering buying from a “research chemical” site
- You have a current or past cancer diagnosis (peptides’ effects on tumors are unknown)
🚨 When to Contact Your Healthcare Provider
Contact your doctor immediately if you experience any of the following:
- Severe injection-site pain, redness or swelling: may indicate contamination or infection.
- Fever or chills: possible systemic infection requiring prompt care.
- Unexplained bruising or bleeding: could signal a clotting problem.
- Sudden chest pain or shortness of breath: seek emergency care to rule out a blood clot.
- Severe headache or vision changes: could indicate elevated blood pressure or neurological issues.
- New mood changes, depression or suicidal thoughts: stop the peptide and call or text the 988 Suicide & Crisis Lifeline (available 24/7).
- Signs of an allergic reaction such as hives, facial swelling or trouble breathing.
- Unexpected worsening of your underlying condition: for example, worsening joint pain instead of improvement.
Scientific References
- Quesada SG, Ahmed Z, Nakamura HS, et al. Access without approval: state-level determinants of peptide availability in sexual medicine. Sex Med. 2026.
- Mateescu DM, Gavrilescu DM, Constantinescu FE, et al. BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers. Pharmaceutics. 2026.
Frequently Asked Questions
Does the policy mean BPC-157 and TB-500 are now FDA-approved?
No. The policy only states that FDA will not enforce against certain compounding activities. None of the six peptides has gone through the FDA approval process.
Is a prescription still required?
Yes. A licensed prescriber must determine a legitimate medical need and write a patient-specific prescription before a pharmacy may compound the peptide.
Are “research use only” peptides safer now that FDA issued this policy?
No. Research-grade products remain outside the policy, unregulated for purity or potency and intended for laboratory use, not people.
How can I tell if my state allows compounding these peptides?
Check your state board of pharmacy website for any bulletins or emergency rules. You can also call the board directly or ask your provider to confirm.
Does the policy set a dose or dosage form?
No. The policy does not set doses or forms. A licensed prescriber decides whether any of these peptides is appropriate for you.
Could FDA revoke the policy?
Yes. The policy is interim, and HHS may reconsider it if safety or quality problems emerge.
